Guardian Pharmacy Services financials
$40.68−0.15%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $351.8M | $336.6M | $397.6M | $377.4M | $344.3M | $329.3M | $338.6M | $314.4M |
| Gross profit | $80.0M | $76.3M | $85.5M | $74.7M | $68.1M | $64.3M | $67.1M | $60.9M |
| Gross margin | 22.8% | 22.7% | 21.5% | 19.8% | 19.8% | 19.5% | 19.8% | 19.4% |
| Operating income | $20.6M | $17.7M | $30.8M | $16.4M | $12.6M | $13.0M | $16.8M | -$104.6M |
| Net income | $21.9M | $13.3M | $20.9M | $9.8M | $9.0M | $9.4M | $11.9M | -$122.0M |
| Net margin | 6.2% | 3.9% | 5.3% | 2.6% | 2.6% | 2.9% | 3.5% | −38.8% |
| Diluted EPS | $0.34 | $0.21 | $0.33 | $0.15 | $0.14 | $0.15 | $0.06 | $-2.00 |
| EBITDA | $26.5M | $23.7M | $36.5M | $22.2M | $18.1M | $18.3M | $21.9M | -$99.6M |
| Operating cash flow | $30.0M | $6.1M | $34.6M | $28.2M | $19.9M | $17.6M | $22.3M | -$2.2M |
| Free cash flow | $25.4M | $1.0M | $25.9M | $19.0M | $6.7M | $11.7M | $14.4M | -$9.5M |
| Diluted shares | 63.8M | 63.7M | 63.6M | 63.4M | 63.2M | 62.9M | 186.9M | 61.1M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $89.8M | $64.9M | $65.6M | $36.5M | $18.8M | $14.0M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $443.6M | $426.9M | $412.7M | $390.0M | $356.3M | $334.0M |
| Total liabilities | $185.9M | $194.5M | $194.7M | $194.5M | $176.7M | $170.8M |
| Shareholders' equity | $257.6M | $232.4M | $217.9M | $195.5M | $179.7M | $163.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology